Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are: Does drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo . Participant will: Take drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 and above

• Patients who meet the Rome IV criteria for IBS-D.

Locations
Other Locations
Bangladesh
Dhaka Medical College
RECRUITING
Dhaka
Contact Information
Primary
Md. Hazrat Ali, MBBS
mhalirmc45@gmail.com
+8801710725424
Time Frame
Start Date: 2025-08-15
Estimated Completion Date: 2026-07
Participants
Target number of participants: 60
Treatments
Active_comparator: Ebastine
Tab. Ebastine 20mg once daily at night
Placebo_comparator: Placebo
Tab. Placebo once daily at night
Sponsors
Leads: Md. Hazrat Ali

This content was sourced from clinicaltrials.gov

Similar Clinical Trials